
Need professional-grade analysis? Visit stockanalysis.com
$803.28B
91.02
809
N/A
Price Chart
Risk-Adjusted Performance
Shinpoong Pharmaceutical Co Ltd (019175) Price Performance
Shinpoong Pharmaceutical Co Ltd (019175) trades on KO in KRW. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at KRW15800.00, up 0.77% from the previous close.
Over the past year, 019175 has traded between a low of KRW11430.00 and a high of KRW46450.00. The stock has gained 37.8% over this period. It is currently 66.0% below its 52-week high.
Shinpoong Pharmaceutical Co Ltd has a market capitalization of $803.28B, with a price-to-earnings ratio of 91.02.
About Shinpoong Pharmaceutical Co Ltd
Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. It provides active pharmaceutical ingredients; Pyramax, an anti-malarial drug; and drugs for treating hypercholesterolemia, knee osteoarthritis and shoulder periarthritis, and surgical adhesion barrier; prescription drugs; wound dressings; health functional food; and over the counter products. In addition, the company engages in business management and exports its products to approximately 50 countries. The company was founded in 1962 and is headquartered in Seoul, South Korea.
Company Info
- Sector
- Healthcare
- Exchange
- KO
- Currency
- KRW
- Country
- South Korea
Financial Metrics
- Revenue (TTM)
- $234.68B
- EBITDA
- $25.65B
- Profit Margin
- 3.76%
- EPS (TTM)
- N/A
- Book Value
- 269975.00
Technical Indicators
- 52 Week High
- ₩55,000.00
- 52 Week Low
- ₩10,850.00
- 50 Day MA
- ₩18,198.40
- 200 Day MA
- ₩23,335.60
- Beta
- 1.27
Valuation
- Trailing P/E
- 91.02
- Forward P/E
- N/A
- Price/Sales
- 3.42
- Price/Book
- 2.95
- Enterprise Value
- $779.50B